ArticleDiagnostics (Basel, Switzerland)2022

Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab.

Marina Fabbi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.